摘要:
A latent additive represented by general formula (1): wherein A is a 5- or 6-membered aromatic or heterocyclic ring; R1 and R2 are each hydrogen, halogen, cyano, hydroxyl, nitro, carboxyl, optionally substituted C1-C40 alkyl, C6-C20 aryl, C7-C20 arylalkyl, or C2-C20 heterocyclic ring-containing group; and R4 is C1-C20 alkyl, C2-C20 alkenyl, C6-C20 aryl, C7-C20 arylalkyl, C2-C20 heterocyclic ring-containing group, or trialkylsilyl.
摘要:
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.
摘要:
The present invention is directed to compounds, intermediates and methods for making valerenic acid and its derivatives as well as the use of such compounds as GABAA receptor ligands.
摘要:
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-6 or encompassed by formulas I-VI) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.
摘要:
Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones, processes for their preparation, fungicidal compositions containing them and methods of using them to treat or prevent fungal disease in crops.
摘要:
We proposed a novel compound having an activity of PGI.sub.2 receptor agonist.A phenoxyacetic acid derivative of the formula ##STR1## A is --C(R.sup.1).dbd.N.about.OR.sup.2, --CH(R)NH--OR.sup.2, --COE, --SO.sub.2 E, --CH.sub.2 --NR.sup.3 --Y, --Z--NR.sup.3 --CONR.sup.4 R.sup.5, --CH.sub.2 --OR.sup.6, --CO.sub.2 R.sup.6, --CH.sub.2 --O.about.N.dbd.CR.sup.7 R.sup.8, --CH.sub.2 --O--NHCHR.sup.7 R.sup.8, substituted by imidazolyl(methyl), pyrazolylmethyl, oxazolyl(methyl), thioxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolylmethyl;T is alkylene, alkenylene, etc.;D is --CO.sub.2 R.sup.10, --CONR.sup.11 R.sup.12 ;E is (substitution) amino, hydradino;Y is substituted (thio) carbonyl, substituted sulfonyl;Z is --CH.dbd.N--, --CH.sub.2 NR.sup.3 --;R.sup.1, R.sup.3, R.sup.10 --R.sup.13 is each H or alkyl, etc.;R.sup.2, R.sup.4 --R.sup.9 is each H, alkyl or alkyl substituted by phenyl or hetero ring ,etc. and non-toxic salts thereof, non-toxic acid addition salts thereof, possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclosis, ischemic heart diseases, gastric ulcer and hypertention.
摘要翻译:我们提出了一种具有PGI2受体激动剂活性的新化合物。 式A的苯氧基乙酸衍生物是-C(R 1)= N分子式OR 2,-CH(R)NH-OR 2,-COE,-SO 2 E,-CH 2 -NR 3 -Y,-Z-NR 3 -CONR 4 R 5,-CH 2 取代的咪唑基(甲基),吡唑基甲基,恶唑基(甲基),噻唑基,异恶唑基,异噻唑基,恶二唑基,三唑基甲基等的取代基的-OR 6,-CO 2 R 6,-CH 2 -O-异构体N = CR 7 R 8,-CH 2 -O-NHCHR 7 R 8。 T是亚烷基,亚烯基等; D是-CO 2 R 10,-CONR 11 R 12; E是(取代)氨基,羟氨基; Y是取代的(硫代)羰基,取代的磺酰基; Z是-CH = N-,-CH 2 NR 3 - ; R1,R3,R10-R13各自为H或烷基等; R2,R4-R9各自为H,被苯基或杂环取代的烷基或烷基等。 其无毒性盐,其无毒性酸加成盐对PGI2受体具有激动作用,因此可用于预防和/或治疗血栓形成,动脉壁炎,缺血性心脏病,胃溃疡和高血压。
摘要:
A fused benzeneoxyacetic acid derivative of the formula (I): ##STR1## A is --COW, --NR.sup.4 --Y or --Z--NR.sup.4 --CONR.sup.2 R.sup.3 ; and salts thereof possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertention.
摘要:
We proposed a novel compound having an activity of PGI.sub.2 receptor agonist.A phenoxyacetic acid derivative of the formula ##STR1## A is --C(R.sup.1).dbd.N.about.OR.sup.2, --CH(R)NH--OR.sup.2, --COE, --SO.sub.2 E, --CH.sub.2 --NR.sup.3 --Y, --Z--NR.sup.3 --CONR.sup.4 R.sup.5, --CH.sub.2 --OR.sup.6, --CO.sub.2 R.sup.6, --CH.sub.2 --O.about.N.dbd.CR.sup.7 R.sup.8, --CH.sub.2 --O--NHCHR.sup.7 R.sup.8, substituted by imidazolyl(methyl), pyrazolylmethyl, oxazolyl(methyl), thioxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolylmethyl;T is alkylene, alkenylene, etc.;D is --CO.sub.2 R.sup.10, --CONR.sup.11 R.sup.12 ;E is (substitution) amino, hydradino;Y is substituted (thio) carbonyl, substituted sulfonyl;Z is --CH.dbd.N--, --CH.sub.2 NR.sup.3 --;R.sup.1, R.sup.3, R.sup. -R.sup.13 is each H or alkyl, etc.;R.sup.2, R.sup.4 -R.sup.9 is each H, alkyl or alkyl substituted by phenyl or hetero ring, etc. and non-toxic salts thereof, non-toxic acid addition salts thereof, possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclosis, ischemic heart diseases, gastric ulcer and hypertention.
摘要翻译:我们提出了一种具有PGI2受体激动剂活性的新化合物。 式(A)的苯氧基乙酸衍生物是-C(R 1)= N分子式OR 2,-CH(R)NH-OR 2,-COE,-SO 2 E,-CH 2 -NR 3 -Y,-Z-NR 3 CONR 4 R 5 (甲基),吡唑基甲基,恶唑基(甲基),噻唑基,异恶唑基,异噻唑基,恶二唑基,三唑基甲基等的取代的-CH2-OR6,-CO2R6,-CH2-O-取代的N = CR7R8,-CH2-O-NHCHR7R8。 T是亚烷基,亚烯基等; D是-CO 2 R 10,-CONR 11 R 12; E是(取代)氨基,羟氨基; Y是取代的(硫代)羰基,取代的磺酰基; Z是-CH = N-,-CH 2 NR 3 - ; R 1,R 3,R -R 13各自为H或烷基等; R2,R4-R9各自为H,被苯基或杂环取代的烷基或烷基等,其无毒性盐,其无毒性酸加成盐对PGI2受体具有激动作用,因此可用于预防和 /或治疗血栓形成,动脉炎,缺血性心脏病,胃溃疡和高血压。